Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors

Current Gastroenterology Reports

Volumn 14, Issue 1, 2012, Pages 47-54

  Gambarin Gelwan, Maya ^a   Jacobson, Ira M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Boceprevir (BOC); Chronic hepatitis C (CHC); Protease inhibitors (PI); Resistance associated variants (RAVs); Telaprevir (TVR)

Indexed keywords

ALPHA INTERFERON; AMINO ACID; ANTIVIRUS AGENT; BOCEPREVIR; DANOPREVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5; PEGINTERFERON; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; DRUG BINDING SITE; GENETIC VARIABILITY; HEPATITIS C; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); POINT MUTATION; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS REPLICATION;

DRUG RESISTANCE, VIRAL; GENETIC VARIATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS;

EID: 84857634446     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-011-0237-1     Document Type: Article

References (52)

1. F Poordad J McCone B Bacon, et al. 2011 Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 1195 1206 21449783 10.1056/NEJMoa1010494 1:CAS:528:DC%2BC3MXkt1Chtrc%3D
2. IM Jacobson JG McHutchison G Dusheiko, et al. 2011 Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2405 2416 21696307 10.1056/NEJMoa1012912 1:CAS:528:DC%2BC3MXotVCku7Y%3D
3. BR Bacon SC Gordon E Lawitz, et al. 2011 Boceprevir for previously treated chronic HCV genotype 1 N Engl J Med 364 1207 1217 21449784 10.1056/NEJMoa1009482 1:CAS:528:DC%2BC3MXkt1Cht7k%3D
4. S Zeuzem P Andreone S Pol, et al. 2011 Telaprevir for retreatment of HCV infection N Engl J Med 364 2417 2428 21696308 10.1056/NEJMoa1013086 1:CAS:528:DC%2BC3MXotVCrsrg%3D
5. R Bartenschlager V Lohmann 2000 Replication of hepatitis C virus J Gen Virol 81 Pt7 1631 1648 10859368 1:CAS:528:DC%2BD3cXks12iurg%3D (Pubitemid 30427068)
6. S Duffy LA Shackelton EC Holmes 2008 Rates of evolutionary changes in viruses: patterns and determinants Nat Rev Genet 9 4 267 276 18319742 10.1038/nrg2323 1:CAS:528:DC%2BD1cXjtlGntbo%3D (Pubitemid 351399833)
7. JM Pawlotsky 2003 Hepatitis C virus genetic variability: pathogenic and clinical implications Clin Liver Dis 7 45 66 12691458 10.1016/S1089-3261(02) 00065-X (Pubitemid 36350751)
8. C Sarrazin TL Kieffer D Bartels, et al. 2007 Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 5 1767 1777 17484874 10.1053/j.gastro.2007.02. 037 1:CAS:528:DC%2BD2sXmsVyms7s%3D This paper described in vivo resistance mutations in patients treated with telaprevir. It pointed out that resistant isolates are selected rapidly with telaprevir monotherapy and combination therapy is mandatory to avoid resistance (Pubitemid 46677938)
9. TL Kieffer C Sarrazin JS Miller, et al. 2007 Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replications in patients Hepatology 46 3 631 639 17680654 10.1002/hep.21781 1:CAS:528:DC%2BD2sXhtFWhsr%2FL (Pubitemid 47436107)
10. F Clavel AJ Hance 2004 HIV drug resistance N Engl J Med 350 1023 1035 14999114 1:CAS:528:DC%2BD2cXhvFGjs7c%3D (Pubitemid 38269279)
11. R Thimme V Lohmann F Weber 2006 A target on the move: innate and adaptive immune escape strategies of hepatitis C virus Antiviral Res 69 3 129 141 16413618 10.1016/j.antiviral.2005.12.001 1:CAS:528:DC%2BD28XhsFKkur4%3D (Pubitemid 43247333)
12. Y Zhou DJ Bartels BL Hanzelka, et al. 2008 Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease Antimicrob Agents Chemother 52 110 120 17938182 10.1128/AAC.00863-07 1:CAS:528: DC%2BD1cXksleitw%3D%3D
13. C Welsch FS Domingues S Susser, et al. 2008 Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus Genome Biol 9 R16 18215275 10.1186/gb-2008-9-1-r16 (Pubitemid 351911931)
14. Y Zhou U Muh BL Hanzelka, et al. 2007 Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha J Biol Chem 282 22619 22628 17556358 10.1074/jbc.M610207200 1:CAS:528:DC%2BD2sXot1WjtLc%3D (Pubitemid 47267330)
15. KP Romano A Ali WE Royer CA Schiffer 2010 Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding Proc Natl Acad Sci U S A 37 20986 20991 10.1073/pnas. 1006370107
16. AS Lok F Zoulim S Locarnini, et al. 2007 Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management Hepatology 46 1 254 265 17596850 10.1002/hep.21698 1:CAS:528: DC%2BD2sXosVyltLY%3D (Pubitemid 47171942)
17. AJV Thompson JG McHutchison 2009 Antiviral resistance and specifically targeted therapy for HCV (STAT-C) J Viral Hepat 16 377 387 19472445 10.1111/j.1365-2893.2009.01124.x 1:STN:280:DC%2BD1Mznt1OjsA%3D%3D
18. M Yi X Tong A Skelton, et al. 2006 Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations J Biol Chem 281 12 8205 8215 16352601 10.1074/jbc.M510246200 1:CAS:528:DC%2BD28Xitl2rtro%3D (Pubitemid 43847441)
19. X Tong R Chase A Skelton, et al. 2006 Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034 Antiviral Res 70 28 38 16448708 10.1016/j.antiviral.2005.12.003 1:CAS:528:DC%2BD28Xjs1Wmu7w%3D
20. G Dahl A Sandstrom E Akerblom UH Danielson 2007 Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3 Antivir Ther 12 733 740 17713156 1:CAS:528:DC%2BD2sXpslOls7c%3D (Pubitemid 47235487)
21. V Cento C Mirabelli F Mercurio, et al. 2011 HCV genotypes have different genetic barriers in the generation of resistance mutations to protease inhibitors in advanced clinical development J Hepatol 54 suppl 1 S473 10.1016/S0168-8278(11)61199-9 1197
22. M Flint S Mullen AM Deatly, et al. 2008 Selection and characterization of hepatitis C virus replicon dually resistant to the polymerase and protease inhibitors, HCV-796 and boceprevir (SCH 503034) Antimicrob Agents Chemother 53 2 401 411 18936191 10.1128/AAC.01081-08
23. H Mo J Harris A Bae, et al. 2011 Characterization of viral resistance mutations in genotype 1 HCV patients receiving combination therapy with a protease inhibitor and a polymerase inhibitor with or without ribavirin J Hepatol 54 suppl 1 S484 10.1016/S0168-8278(11)61227-0 1225
24. JG McHutchison GT Everson SC Gordon, et al. 2009 Telaprevir with Peginterferon and Ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 18 1827 1838 19403902 10.1056/NEJMoa0806104 1:CAS:528:DC%2BD1MXlsVGmtrc%3D
25. C Hezode N Forestier G Dusheiko, et al. 2009 Telaprevir and Peginterferon with or without Ribavirin for chronic HCV infection N Engl J Med 360 18 1839 1850 19403903 10.1056/NEJMoa0807650 1:CAS:528:DC%2BD1MXlsVSlurg%3D
26. PY Kwo EJ Lawitz J McCone, et al. 2010 Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomized, multicentre phase 2 trial Lancet 376 9742 705 716 20692693 10.1016/S0140-6736(10)60934-8 1:CAS:528:DC%2BC3cXhtVymt7zP
27. BS Adiwijaya E Herrmann B Hare, et al. 2010 A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants PLoS Comput Biol 6 e1000745 20419154 10.1371/journal.pcbi.1000745
28. S Susser C Welsch Y Wang, et al. 2009 Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients Hepatology 50 1709 1718 19787809 10.1002/hep.23192 1:CAS:528:DC%2BD1MXhs1SjurrJ This manuscript identified resistance mutations during boceprevir monotherapy with all mutations showing cross-resistance to telaprevir. While impaired replicative fitness was revealed for single mutations, for combined mutations a relative increase in replication efficiency was suggested by mathematical modeling
29. C Brass RJO Barnard JA Howe, et al. 2011 Sustained virologic response and boceprevir resistance -associated variants observed in patients infected with HCV genotype 1A/1B when treated with boceprevir plus peginterferon alfa-2b/ribavirin J Hepatol 54 suppl 1 S471 10.1016/S0168-8278(11)61196-3 1194
30. S Zeuzem RJ Barnard JA Howe, et al. 2011 Boceprevir resistance-associated variants (RAVs) are observed more frequently in HCV (GT1)-infected patients with poor response to peginterferon alfa-2b/ribavirin J Hepatol 54 suppl 1 S4 (9) This recent oral presentation at EASL, suggested that interferon responsiveness is highly predictive of development of boceprevir RAVs. This observation has significant implications in re-treatment of prior null-responders with a single DAA agent
31. T Verbinnen H Van Marck I Vandenbroucke, et al. 2010 Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing J Virol 84 11124 11133 20739521 10.1128/JVI.01217-10 1:CAS:528:DC%2BC3cXhsVeisLfL
32. T Kuntzen J Timm A Berical, et al. 2008 Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients Hepatology 48 6 1769 1778 19026009 10.1002/hep.22549 This multicenter, international study demonstrated that naturally-occurring resistant mutations to DAAs are common in treatment-naïve HCV G1 patients. It posed the question whether drug-resistance testing would be of benefit for individual tailoring of therapy
33. DJ Bartels Y Zhou EZ Zhang, et al. 2008 Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3/4A protease inhibitors in treatment-naïve subjects J Infect Dis 198 6 800 807 18637752 10.1086/591141 1:CAS:528:DC%2BD1cXhtFygs7rE
34. MF McCown S Rajyaguru S Kular, et al. 2009 GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796 Antimicrob Agents Chemother 53 2129 2132 19273674 10.1128/AAC.01598-08 1:CAS:528:DC%2BD1MXlvVGgu7Y%3D
35. S Gaudieri T Applegate M Tshochner, et al. 2011 Signature resistance mutations to directly acting antiviral agents occur at low prevalence in treatment-naïve subjects with recently acquired hepatitis C infection J Hepatol 54 suppl 1 S184 S185 10.1016/S0168-8278(11)60455-8 453
36. S Chevalier C Rodriguez A Soulier, et al. 2011 Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations J Hepatol 54 suppl 1 S30 10.1016/S0168-8278(11)60069-X 67
37. JM Vierling PY Kwo EJ Lawitz, et al. 2010 Frequencies of resistance-associated amino acid variants following combination treatment with boceprevir plus Peginteron (peginterferon alfa-2b)/ribavirin in patients with chronic hepatitis C (CHC), genotype 1 (G1) Hepatology 52 Suppl 702A 801
38. JA Howe P Qiu RA Ogert, et al. 2011 Frequencies of resistance-associated amino acid variants detected by 454-sequencing during combination treatment with boceprevir plus PegIntron (peginterferon alfa-2b)/ribavirin in HCV (GT1)-infected patients J Hepatol 54 suppl 1 S176 10.1016/S0168-8278(11)60435-2 433
39. HCV GenoSure® NS3/4A breaking ground in HCV drug resistance testing. Available at http://www.monogrambio.com/pdf/HCV-GS-NS34A.pdf. Accessed Sept 2011.
40. D Moradpour F Penin CM Rice 2007 Replication of hepatitis C virus Nat Rev Microbiol 5 453 463 17487147 10.1038/nrmicro1645 1:CAS:528:DC%2BD2sXltlSqtb8%3D (Pubitemid 46780082)
41. JM Pawlotsky 2011 Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 1742 1751 21374691 10.1002/hep.24262 1:CAS:528:DC%2BC3MXltVynsr4%3D
42. N Forestier S Susser MW Welker, et al. 2008 Long term follow up of patients previously treated with telaprevir Hepatology 48 4 Suppl 1 760A 1011
43. X Tong S Bogen R Chase, et al. 2008 Characterization of resistance mutations against HCV ketoamide protease inhibitors Antiviral Res 77 3 177 185 18201776 10.1016/j.antiviral.2007.11.010 1:CAS:528:DC%2BD1cXhsl2htb4%3D
44. S Zeuzem MS Sulkowski F Zoulim, et al. 2010 Long-term follow up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2A and ribavirin: interim analysis of the EXTEND study Hepatology 52 Suppl 436A 227
45. S De Meyer I Dierynck A Ghys, et al. 2011 Characterization of HCV variants in non-SVR patients in REALIZE study suggests that telaprevir exhibits a consistent resistance profile irrespective of a lead-in J Hepatol 54 suppl 1 S475 10.1016/S0168-8278(11)61204-X 1202
46. JS Sullivan S De Meyer DJ Bartels, et al. 2011 Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials J Hepatol 54 suppl 1 S4 10.1016/S0168-8278(11)60010-X 8
47. XV Thomas J de Bruijne TL Kieffer, et al. 2011 Long-term follow-up of chronic hepatitis C infected patients treated with telaprevir: evaluation of persistence of resistant variants by ultra-deep sequencing J Hepatol 54 suppl1 S490 S491 10.1016/S0168-8278(11)61244-0 1242
48. JM Vierling R Ralston EJ Lawitz, et al. 2010 Long-term outcomes following combination treatment with boceprevir plus Peg-Intron/ribavirin (P/R) in patients with chronic hepatitis C, genotype 1 (CHC-G1) J Hepatol 52 Suppl 1 S470 10.1016/S0168-8278(10)61207-X 201
49. C Charpentier DE Dwyer F Mammano, et al. 2004 Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors J Virol 78 4234 4247 15047838 10.1128/JVI.78.8.4234-4247.2004 1:CAS:528:DC%2BD2cXjtFWltLw%3D (Pubitemid 38437228)
50. RF Siliciano 2005 Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution Top HIV Med 13 96 100 16170226
51. Y He M King D Kempf, et al. 2008 Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus NS3 protease mutants in the HCV genotype 1b replicon system Antimicrob Agents Chemother 52 1101 1110 18086851 10.1128/AAC.01149-07 1:CAS:528: DC%2BD1cXivFalt70%3D (Pubitemid 351358394)
52. JG McHutchison MP Manns AJ Muir for the PROVE3 Study Team, et al. 2010 Telaprevir for previously treated chronic HCV infection N Engl J Med 362 1292 1303 20375406 10.1056/NEJMoa0908014 1:CAS:528:DC%2BC3cXksVyntrg%3D